Prof. Dr. Christof von Kalle

Managing Director, NCT Heidelberg
Translational Oncology

Phone: +49 6221 56-6990 / -6991
Fax: +49 6221 56-6967

Professor Christof von Kalle has been head of the Department of Translational Oncology at the DKFZ/NCT since July 2005. A physician and scientist with a clinical background in hematology and oncology, he is an internationally renowned, leading scientist in the area of stem cell research, mutation analysis and gene transfer with more than 150 publications in high impact journals.

He heads the DKFZ research program Translational Cancer Research, he is Deputy Chairman of the DKFZ Scientific Council, spokesperson of the Helmholtz initiative on personalized medicine iMed, spokesperson of the Comprehensive Cancer Center Network of German Cancer Aid, and member of the steering committee for various projects financed by the EU, DFG, BMBF, DKH and the German ICGC Consortium.

Christoph von Kalle coordinates the NCT's strategic orientation with the primary objective to use state-of-the-art scientific knowledge in translational and clinical research at DKFZ and Heidelberg University Hospital for targeted diagnostics, therapy and cancer prevention. Scientists and physicians from the Translational Oncology unit support patient care and the development of clinical studies at the NCT, and head internationally renowned research groups for stem cell research, molecular gene therapy, molecular and cellular oncology, lymphoma research, applied functional genomics and virotherapy. In the field of precision oncology, the Translational Oncology department coordinates the NCT Personalized Oncology Program NCT POP. The main focus is always the development of individualized cancer therapies for every single patient at the NCT.

MD, University of Cologne Medical School, Germany

Subinternship, Albert Einstein Medical School, New York, USA, Sloan Kettering Cancer Center and Cornell University Medical Center, New York, USA


Medical PhD Degree, Post-doctoral Research Fellow and Clinical Junior Resident, Department of Internal Medicine, University of Cologne Medical School, Germany

Associate in Clinical Research, Program of Transplantation Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Clinical Investigator and Senior Resident, Department of Internal Medicine, University of Cologne Medical School, Germany

Senior Clinical Investigator, Gene Therapy Program, and Senior Medical Staff Fellow, Department of Internal Medicine, Freiburg University Medical School

Group Leader, Section of Hematopoiesis and Gene Transfer, Institute for Molecular Medicine, Freiburg University, Germany

Tenured Associate Professor of Internal Medicine, Freiburg University, Germany
2002–2005 Associate Professor of Pediatrics, Program Leader “Gene and Molecular Therapy”, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA


Adjunct Professor of Pediatrics, Cincinnati Children’s Hospital Medical Center, Division of Experimental Hematology, Cincinnati, OH, USA

Chair, Board of Directors, NCT, Director Department of Translational Oncology, NCT and DKFZ, Heidelberg, Germany

  • American Association for the Advancement of Science (AAAS),
  • American Association for Cancer Research (AACR)
  • American Society for Cell Biology (ASCB)
  • American Society for Clinical Investigation (ASCI)
  • American Society of Clinical Oncology (ASCO)
  • American Society of Gene Therapy (ASGT)
  • American Society of Hematology (ASH)
  • European Society of Gene and Cell Therapy (ESGCT)
  • European Society for Medical Oncology (ESMO)
  • European Association for Cancer Research (EACR)
  • European Cancer Organization (ECCO)
  • International Society for Stem Cell Research (ISSCR) International Society for Experimental Hematology (ISEH)
  • Deutsche Gesellschaft für Gentherapie (DG-GT)
  • Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)

Best Presentation Award, German Society of Hematology/Oncology (DGHO)

van Bekkum Award, European Group for Blood and Marrow Transplantation (EBMT)

>20  Best Presentation Awards from ESGT, ASH and ASGT (Sen. Author)

Young Investigator Award, American Society of Gene Therapy (ASGT)

Elected, American Society of Clinical Investigation (ASCI)

Langen Research Award, Paul-Ehrlich-Institute, Langen, Germany

Eva Luise Köhler Award for Rare Diseases

Pioneer Series Award, Human Gene Therapy

  • Haematology and oncology
  • Short and long term hematopoiesis
  • Clinical research
  • Molecular and gene therapy for cancer and inherited diseases
  • Cancer stem cells
  • Retrovirology
  • Coordinator of the Cross-Program initiative – Personalized Medicine (iMed) of the Helmholtz Association
  • Chair of the Comprehensive Cancer Center Network of German Cancer Aid
  • Member of the Board, DG-GT
  • Member of the Board and Treasurer, EACR, ESGCT
  • Work package leader of EU funded projects (TRiPoD, AIPGene, Eurofancolen, DiaBil-2, Net4CGD, Supersist)
  • Steering committee member of program project grants funded by EU, DFG, BMBF, DKH, and the German ICGC Consortium
  • Invited advisor for the EMEA, the DFG and BMBF
  • Board of Directors, Meyenburg Foundation
  • Reviewer for Nature, Nature Medicine, Nature Methods, Nature Biotechnology, Science, Journal of Clinical Investigation, Blood
Jasmin Schwab, M.A.

Phone: +49 6221 56-6762
Fax: +49 6221 56-6967

Andrea Fries

Phone: +49 6221 56-6762
Fax: +49 6221 56-6967

Dr. Eva Lempp

Executive Assistant
Phone: +49 6221 56-38229
Fax: +49 6221 56-6967

NCT Network Coordinator
Phone: +49 6221 56-6794
Fax: +49 6221 56-6967

Dr. Maria Rius

Personal Assistant to the Director
Phone: +49 6221 56-35898
Fax: +49 6221 56-6967

Dr. Stefanie Rudolph

Scientific Coordinator
Phone: +49 6221 56-32875
Fax: +49 6221 56-6967

Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, Hermann M, Herold M, Weichert W, Dearden C, Haferlach T, Seiffert M, Hallek M, von Kalle C, Ho AD, Gaehler A, Andrulis M, Steurer M, Zenz T. BRAF inhibition in hairy cell leukemia with low dose vemurafenib.Blood. 2016 Mar 3. pii: blood-2015-11-680074.

1. Oliveira G, Ruggiero E, Stanghellini MT, Cieri N, D'Agostino M, Fronza R, Lulay C, Dionisio F, Mastaglio S, Greco R, Peccatori J, Aiuti A, Ambrosi A, Biasco L, Bondanza A, Lambiase A, Traversari C, Vago L, von Kalle C, Schmidt M, Bordignon C, Ciceri F, Bonini C. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Sci Transl Med 2015 7(317):317ra198. Erratum in: Sci Transl Med 2015 7(319):319er9.

2. Naldini L, Schumacher T, von Kalle C, Thrasher A, Bordignon C. Toward Clinical Translation of New Gene Targeting Technologies for Correcting Inherited Mutations and Empowering Adoptive Immunotherapy of Cancer (SUPERSIST). Human Gene Therapy. Clinical Development 2015; 26(2):95-97.

3. Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S. Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia 2015 Nov 19. doi: 10.1038/leu.2015.319. [Epub ahead of print].

4. Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Gabriel R, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, Schmidt M, Hippen KL, Miller JS, Scharenberg AM, Tolar J, Blazar BR. Evaluation of TCR Gene Editing achieved by TALENs, CRISPR/Cas9 and megaTAL nucleases. Mol Ther 2015 Oct 27. doi: 10.1038/mt.2015.197. [Epub ahead of print].

5. Molina-Estevez FJ, Nowrouzi A, Lozano M, Galy A, Charrier S, von Kalle C, Guenechea G, Bueren JA, Schmidt M. Lentiviral-mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs. Curr Gene Ther 2015; 15(6):550-562.

6. Ruggiero E, Nicolay JP, Fronza R, Arens A, Paruzynski A, Nowrouzi A, Ürenden G, Lulay C, Schneider S, Goerdt S, Glimm H, Krammer PH, Schmidt M, von Kalle C. High-resolution analysis of the human T-cell receptor repertoire. Nat Commun 2015; 6:8081. DOI: 10.1038/ncomms9081.

7. Grömminger S, Erkan S, Schöck U, Stangier K, Bonnet J, Schloo R, Schubert A, Prott EC, Knoll U, Stumm M, von Kalle C, Hofmann W. The Influence of Low Molecular Weight Heparin Medication on Plasma DNA in Pregnant Women. Prenat Diagn 2015; Aug 6. doi: 10.1002/pd.4668. [Epub ahead of print].

8. Schuol S, Schickhardt C, Wiemann S, Bartram CR, Tanner K, Eils R, Meder B, Richter D, Glimm H, von Kalle C, Winkler EC. So rare we need to hunt for them: reframing the ethical debate on incidental findings. Genome Med 2015; Jul 30;7(1):83. doi: 10.1186/s13073-015-0198-3. eCollection 2015.

9. Sundarasetty BS, Kloess S, Oberschmidt O, Naundorf S, Kuehlcke K, Daenthanasanmak A, Gerasch L, Figueiredo C, Blasczyk R, Ruggiero E, Fronza R, Schmidt M, von Kalle C, Rothe M, Ganser A, Koehl U, Stripecke R. Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation. J Transl Med 2015; 13:240.

10. Richards DM, Ruggiero E, Hofer AC, Sefrin JP, Schmidt M, von Kalle C, Feuerer M. The Contained Self-Reactive Peripheral T Cell Repertoire: Size, Diversity, and Cellular Composition. J Immunol 2015; 195(5):2067-79.

11. Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oleś M, Else M, Liu X, Słabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood 2015; 126(8):1005-8.

12. Giordano FA, Appelt JU, Link B, Gerdes S, Lehrer C, Scholz S, Paruzynski A, Roeder I, Wenz F, Glimm H, von Kalle C, Grez M, Schmidt M, Laufs S. High-throughput monitoring of integration site clonality in preclinical and clinical gene therapy studies. Mol Ther Methods Clin Dev 2015 Apr 1;2:14061. doi: 10.1038/mtm.2014.61. eCollection 2015.

13. Daenthanasanmak A, Salguero G, Sundarasetty BS, Waskow C, Cosgun KN, Guzman CA, Riese P, Gerasch L, Schneider A, Ingendoh A, Messerle M, Gabaev I, Woelk B, Ruggiero E, Schmidt M, von Kalle C, Figueiredo C, Eiz-Vesper B, von Kaisenberg C, Ganser A, Stripecke R. Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV. Mol Ther Methods Clin Dev 2015 Jan 7;1:14060. doi: 10.1038/mtm.2014.60. eCollection 2015.

14. Sundarasetty BS, Chan L, Darling D, Giunti G, Farzaneh F, Schenck F, Naundorf S, Kuehlcke K, Ruggiero E, Schmidt M, von Kalle C, Rothe M, Hoon DS, Gerasch L, Figueiredo C, Koehl U, Blasczyk R, Gutzmer R, Stripecke R. Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2 positive melanoma. Gene Ther 2015; 22(9):707-20.

15. Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015; 15(1):392.

16. Corrigan-Curay J, O'Reilly M, Kohn DB, Cannon PM, Bao G, Bushman FD, Carroll D, Cathomen T, Joung JK, Roth D, Sadelain M, Scharenberg AM, von Kalle C, Zhang F, Jambou R, Rosenthal E, Hassani M, Singh A, Porteus MH. Genome editing technologies: defining a path to clinic. Mol Ther 2015; 23(5):796-806.

17. Bergot AS, Chaara W, Ruggiero E, Mariotti-Ferrandiz E, Dulauroy S, Schmidt M, von Kalle C, Six A, Klatzmann D. TCR sequences and tissue distribution discriminate the subsets of naïve and activated/memory Treg cells in mice. Eur J Immunol 2015; 45(5):1524-34.

18. Gabriel, R, von Kalle, C, Schmidt, M. Mapping the precision of genome editing. Nat Biotechnol 2015; 33(2):150-152.

19. Siler U, Paruzynski A, Holtgreve-Grez H, Kuzmenko E, Koehl U, Renner ED, Alhan C, de Loosdrecht AA, Schwäble J, Pfluger T, Tchinda J, Schmugge M, Jauch A, Naundorf S, Kühlcke K, Notheis G, Güngor T, Kalle CV, Schmidt M, Grez M, Seger R, Reichenbach J. Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing. Curr Gene Ther 2015; 15(4):416-27.

20. Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN, Jarjour J, Starker CG, Wagner JE, Joung JK, Voytas DF, von Kalle C, Schmidt M, Blazar BR, Tolar J. Fanconi Anemia Gene Editing by the CRISPR/Cas9 System. Hum Gene Ther 2015; 26(2):114-26; Epub ahead of print 2014 Dec 29.

21. Negre O, Bartholomae C, Beuzard Y, Cavazzana M, Christiansen L, Courne C, Deichmann A, Denaro M, Dreuzy Ed, Finer M, Fronza R, Gillet-Legrand B, Joubert C, Kutner R, Leboulch P, Maouche L, Paulard A, Pierciey FJ, Rothe M, Ryu B, Schmidt M, Kalle Cv, Payen E, Veres G. Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease. Curr Gene Ther 2015; 15(1):64-81.

22. Gardyan A, Osen W, Zörnig I, Podola L, Agarwal M, Aulmann S, Ruggiero E, Schmidt M, Halama N, Leuchs B, von Kalle C, Beckhove P, Schneeweiss A, Jäger D, Eichmüller SB. Identification of NY-BR-1-specific CD4+ T cell epitopes using HLA-transgenic mice. Int J Cancer 2015; 136(11):2588-97. Epub ahead of print 2014 Nov 12.

23. Papanikolaou E, Paruzynski A, Kasampalidis I, Deichmann A, Stamateris E, Schmidt M, Kalle CV, Anagnou NP. Cell Cycle Status of CD34+ Hemopoietic Stem Cells Determines Lentiviral Integration in Actively Transcribed and Development-related Genes. Mol Ther 2015; 23(4):683-96. Epub ahead of print 2014 Dec 19.

24. Qamar Saeed M, Dufour N, Bartholmae C, Sieranska U, Knopf M, Thierry E, Thierry S, Delelis O, Grandchamp N, Pilet H, Ravassard P, Massonneau J, Pflumio F, von Kalle C, Lachapelle F, Bemelmans AP, Schmidt M, Serguera C. Comparison Between Several Integrase-defective Lentiviral Vectors Reveals Increased Integration of an HIV Vector Bearing a D167H Mutant. Mol Ther Nucleic Acids 2014 Dec 2;3:e213.

25. Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umanksy V, Nettelbeck DM, Weichert W, Jäger D, von Kalle C, Ungerechts G. Mol Ther 2014; 22(11):1949-59.

26. Baertsch MA, Leber MF, Bossow S, Singh M, Engeland CE, Albert J, Grossardt C, Jäger D, von Kalle C, Ungerechts G. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus. Cancer Gene Ther 2014; 21(9):373-8010.

27. Northcott PA, Lee C, Zichner T, Stütz AM, Erkek S, Kawauchi D, Shih DJ, Hovestadt V, Zapatka M, Sturm D, Jones DT, Kool M, Remke M, Cavalli FM, Zuyderduyn S, Bader GD, VandenBerg S, Esparza LA, Ryzhova M, Wang W, Wittmann A, Stark S, Sieber L, Seker-Cin H, Linke L, Kratochwil F, Jäger N, Buchhalter I, Imbusch CD, Zipprich G, Raeder B, Schmidt S, Diessl N, Wolf S, Wiemann S, Brors B, Lawerenz C, Eils J, Warnatz HJ, Risch T, Yaspo ML, Weber UD, Bartholomae CC, von Kalle C, Turányi E, Hauser P, Sanden E, Darabi A, Siesjö P, Sterba J, Zitterbart K, Sumerauer D, van Sluis P, Versteeg R, Volckmann R, Koster J, Schuhmann MU, Ebinger M, Grimes HL, Robinson GW, Gajjar A, Mynarek M, von Hoff K, Rutkowski S, Pietsch T, Scheurlen W, Felsberg J, Reifenberger G, Kulozik AE, von Deimling A, Witt O, Eils R, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Korbel JO, Wechsler-Reya RJ, Pfister SM. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 2014; 24; 511(7510):428-34.

28. Valentini V, Abrahamsson PA, Aranda SK, Astier A, Audisio RA, Boniol M, Bonomo L, Brunelli A, Bultz B, Chiti A, De Lorenzo F, Eriksen JG, Goh V, Gospodarowicz MK, Grassi L, Kelly J, Kortmann RD, Kutluk T, Plate A, Poston G, Saarto T, Soffietti R, Torresin A, van Harten WH, Verzijlbergen JF, von Kalle C, Poortmans P. Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper (Annals Oncology Jan;25(1): 9-15, 2014). Ann Oncol 2014; 25(9):1863-5.

29. Gabriel R, Kutschera I, Bartholomae CC, von Kalle C, Schmidt M. Linear amplification mediated PCR - localization of genetic elements and characterization of unknown flanking DNA. J Vis Exp 2014 Jun 25;(88). doi: 10.3791/51543.

30. von Kalle C, Deichmann A, Schmidt M. Vector integration and tumorigenesis. Hum Gene Ther 2014; 25(6):475-81.

31. Kaeppel C, Beattie SG, Fronza R, van Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, von Kalle C, Petry H, Gaudet D, Schmidt M. Reply to: NGS library preparation may generate artifactual integration sites of AAV vectors. Nat Med 2014; 20(6):578-9.

32. Hovestadt V, Jones DT, Picelli S, Wang W, Kool M, Northcott PA, Sultan M, Stachurski K, Ryzhova M, Warnatz HJ, Ralser M, Brun S, Bunt J, Jäger N, Kleinheinz K, Erkek S, Weber UD, Bartholomae CC, von Kalle C, Lawerenz C, Eils J, Koster J, Versteeg R, Milde T, Witt O, Schmidt S, Wolf S, Pietsch T, Rutkowski S, Scheurlen W, Taylor MD, Brors B, Felsberg J, Reifenberger G, Borkhardt A, Lehrach H, Wechsler-Reya RJ, Eils R, Yaspo ML, Landgraf P, Korshunov A, Zapatka M, Radlwimmer B, Pfister SM, Lichter P. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 2014; 510(7506):537-41.

33. Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, Milde T, Bourdeaut F, Ryzhova M, Sturm D, Pfaff E, Stark S, Hutter S, Seker-Cin H, Johann P, Bender S, Schmidt C, Rausch T, Shih D, Reimand J, Sieber L, Wittmann A, Linke L, Witt H, Weber UD, Zapatka M, König R, Beroukhim R, Bergthold G, van Sluis P, Volckmann R, Koster J, Versteeg R, Schmidt S, Wolf S, Lawerenz C, Bartholomae CC, von Kalle C, Unterberg A, Herold-Mende C, Hofer S, Kulozik AE, von Deimling A, Scheurlen W, Felsberg J, Reifenberger G, Hasselblatt M, Crawford JR, Grant GA, Jabado N, Perry A, Cowdrey C, Croul S, Zadeh G, Korbel JO, Doz F, Delattre O, Bader GD, McCabe MG, Collins VP, Kieran MW, Cho YJ, Pomeroy SL, Witt O, Brors B, Taylor MD, Schüller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM; ICGC PedBrain Tumor Project. Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell 2014; 25(3):393-405.

34. Lu-Nguyen NB, Broadstock M, Schliesser MG, Bartholomae C, von Kalle C, Schmidt M, Yáñez-Muñoz RJ. Transgenic expression of human glial cell line-derived neurotrophic factor (hGDNF) from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease. Hum Gene Ther 2014; 25(7):631-41.

35. Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, Modlich U, Beier R, Göhring G, Steinemann D, Fronza R, Ball CR, Haemmerle R, Naundorf S, Kühlcke K, Rose M, Fraser C, Mathias L, Ferrari R, Abboud MR, Al-Herz W, Kondratenko I, Maródi L, Glimm H, Schlegelberger B, Schambach A, Albert MH, Schmidt M, von Kalle C, Klein C. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med 2014; 6(227):227ra33.

36. Ketzer P, Kaufmann JK, Engelhardt S, Bossow S, von Kalle C, Hartig JS, Ungerechts G, Nettelbeck DM. Artificial riboswitches for gene expression and replication control of DNA and RNA viruses. Proc Natl Acad Sci U S A 2014; 111(5):E554-62.

37. Cesana D, Ranzani M, Volpin M, Bartholomae C, Duros C, Artus A, Merella S, Benedicenti F, Sergi LS, Sanvito F, Brombin C, Nonis A, Serio CD, Doglioni C, von Kalle C, Schmidt M, Cohen-Haguenauer O, Naldini L, Montini E. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther 2014; 22(4):774-85.

38. Pañeda MA, Lopez-Franco E, Kaeppel C, Unzu C, Gil-Royo AG, D'Avola D, Beattie SG, Olague C, Ferrero R, Sampedro A, Mauleon I, Hermening S, Salmon F, Benito A, Gavira JJ, Cornet ME, Municio MD, von Kalle C, Petry H, Prieto J, Schmidt M, Fontanellas A, Gonzalez-Aseguinolaza G. Safety and liver transduction efficacy of rAAV5-cohPBGD in non-human primates: A potential therapy for Acute Intermitent Porphyria. Hum Gene Ther 2013; 24(12):1007-17.

39. Jethwa A, Hüllein J, Stolz T, Blume C, Sellner L, Jauch A, Sill M, Kater AP, Te Raa GD, Geisler C, van Oers M, Dietrich S, Dreger P, Ho AD, Paruzynski A, Schmidt M, von Kalle C, Glimm H, Zenz T. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br J Haematol 2013; 163(4):496-500.

40. Hadaschik B, Pahernik S, Grüllich C, Sültmann H, Jäger D, von Kalle C, Duensing S, Hohenfellner M. Urology in the concept of comprehensive cancer centers. Urologe A 2013; 52(9):1283-9.

41. Suwanmanee T, Hu G, Gui T, Bartholomae CC, Kutschera I, von Kalle C, Schmidt M, Monahan PE, Kafri T. Integration-deficient lentiviral vectors expressing codon-optimized R338LhFIX restore normal hemostasis in hemophilia B mice. Mol Ther 2013; 22(3):567-74.

42. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NA, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L. Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy. Science 2013; 341(6148):1233158.

43. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC, Bosticardo M, Evangelio C, Assanelli A, Casiraghi M, Di Nunzio S, Callegaro L, Benati C, Rizzardi P, Pellin D, Di Serio C, Schmidt M, Von Kalle C, Gardner J, Mehta N, Neduva V, Dow DJ, Galy A, Miniero R, Finocchi A, Metin A, Banerjee P, Orange J, Galimberti S, Valsecchi MG, Biffi A, Montini E, Villa A, Ciceri F, Roncarolo MG, Naldini L. Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome. Science 2013; 341(6148):1233151.

44. Stein S, Scholz S, Schwaeble J, Sadat MA, Modlich U, Schultze-Strasser S, Diaz M, Chen-Wichmann L, Mueller-Kuller U, Brendel C, Fronza R, Kaufmann KB, Naundorf S, Pech NK, Travers JB, Matute JD, Presson Jr RG, Sandusky GE, Kunkel H, Rudolf E, Dillmann A, von Kalle C, Kuehlcke K, Baum C, Schambach A, Dinauer MC, Schmidt M, Grez M. From Bench to Bedside: Preclinical Evaluation of a SIN gammaretroviral vector for the Gene Therapy of X-linked Chronic Granulomatous Disease. Hum Gene Ther Clin Dev 2013; 24(2):86-98.

45. Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stütz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger M, Schuhmann MU, Cho YJ, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo ML, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P; the International Cancer Genome Consortium PedBrain Tumor Project, Pfister SM. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013; 45(8):927-32.

46. Kaeppel C, Beattie SG, Fronza R, van Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, von Kalle C, Petry H, Gaudet D, Schmidt M. A largely random AAV integration profile after LPLD gene therapy. Nat Med 2013; 19(7):889-91.

47. Tubsuwan A, Abed S, Deichmann A, Kardel MD, Bartholomä C, Cheung A, Negre O, Kadri Z, Fucharoen S, von Kalle C, Payen E, Chrétien S, Schmidt M, Eaves CJ, Leboulch P, Maouche-Chrétien L. Parallel Assessment of Globin Lentiviral Transfer in Induced Pluripotent Stem Cells and Adult Hematopoietic Stem Cells Derived from the Same Transplanted β-Thalassemia Patient. Stem Cells 2013; 163(4):496-500.

48. Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Fröhling S, von Kalle C, Glimm H, Ho AD, Zenz T. Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia. J Clin Oncol 2013; 31(19):e300-3.

49. Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G. GM-CSF-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther 2013; 24(7):644-54.

50. Hüllein J, Jethwa A, Stolz T, Blume C, Sellner L, Sill M, Langer C, Jauch A, Paruzynski A, von Kalle C, Schmidt M, Glimm H, Zenz T. Next-generation sequencing of cancer consensus genes in lymphoma. Leuk Lymphoma 2013; 54(8):1831-5.

51. Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, Defeo AP, Gabriel R, Schmidt M, von Kalle C, Carlson DF, Maeder ML, Joung JK, Wagner JE, Voytas DF, Blazar BR, Tolar J. TALEN-based Gene Correction for Epidermolysis Bullosa. Mol Ther 2013; 1(6):1151-9.

52. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013; 23(2):159-70.

53. Ranzani M, Cesana D, Bartholomae CC, Sanvito F, Pala M, Benedicenti F, Gallina P, Sergi LS, Merella S, Bulfone A, Doglioni C, von Kalle C, Kim YJ, Schmidt M, Tonon G, Naldini L, Montini E. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods 2013; 10(2):155-61.

54. Scaramuzza S, Biasco L, Ripamonti A, Castiello MC, Loperfido M, Draghici E, Hernandez RJ, Benedicenti F, Radrizzani M, Salomoni M, Ranzani M, Bartholomae CC, Vicenzi E, Finocchi A, Bredius R, Bosticardo M, Schmidt M, von Kalle C, Montini E, Biffi A, Roncarolo MG, Naldini L, Villa A, Aiuti A. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich Syndrome. Mol Ther 2013; 21(1):175-84. Epub 2012, Feb 28.

55. Nowrouzi A, Cheung WT, Li T, Zhang X, Arens A, Paruzynski A, Waddington SN, Osejindu E, Reja S, von Kalle C, Wang Y, Al-Allaf F, Gregory L, Themis M, Holder M, Dighe N, Ruthe A, Buckley SMK, Bigger B, Montini E, Thrasher AJ, Andrews R, Roberts, TP, Newbold RF, Coutelle C, Schmidt M (co-senior author), Themis M. The Fetal Mouse Is a Sensitive Genotoxicity Model That Exposes Lentiviral-associated Mutagenesis Resulting in Liver Oncogenesis. Molecular Therapy 2013; 21(2):324-37. Epub 2012, Nov 13.

56. Cornils K, Bartholomae CC, Thielecke L, Lange C, Arens A, Glauche I, Mock U, Riecken K, Gerdes S, von Kalle C, Schmidt M, Roeder I, Fehse B. Comparative clonal analysis of reconstitution kinetics after transplantation of haematopoietic stem cells gene-marked with a lentiviral SIN or a γ-retroviral LTR vector. Exp Hematol 2013; 41(1):28-38. Epub 2012, Sep 15.

57. Kaufmann JK, Bossow S, Grossardt C, Sawall S, Kupsch J, Erbs P, Hassel JC, von Kalle C, Enk AH, Nettelbeck DM, Ungerechts G. Chemovirotherapy of Malignant Melanoma with a Targeted and Armed Oncolytic Measles Virus. J Invest Dermatol 2013; 133(4):1034-422012 Epub 2012 Dec 6.

58. Gabriel R, Schmidt M, von Kalle C. Integration of retroviral vectors. Curr Opin Immunol 2012; 24(5):592-597.

59. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stütz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber UD, Wang Q, Lasitschka B, Bartholomae CC, Schmidt M, von Kalle C, Ast V, Lawerenz C, Eils J, Kabbe R, Benes V, van Sluis P, Koster J, Volckmann R, Shih D, Betts MJ, Russell RB, Coco S, Paolo Tonini G, Schüller U, Hans V, Graf N, Kim YJ, Monoranu C, Roggendorf W, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, von Deimling A, Witt O, Maass E, Rössler J, Ebinger M, Schuhmann MU, Frühwald MC, Hasselblatt M, Jabado N, Rutkowski S, von Bueren AO, Williamson D, Clifford SC, McCabe MG, Peter Collins V, Wolf S, Wiemann S, Lehrach H, Brors B, Scheurlen W, Felsberg J, Reifenberger G, Northcott PA, Taylor MD, Meyerson M, Pomeroy SL, Yaspo ML, Korbel JO, Korshunov A, Eils R, Pfister SM, Lichter P. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488(7409):100-5.

60. Martins VC, Ruggiero E, Schlenner SM, Madan V, Schmidt M, Fink PJ, von Kalle C, Rodewald HR. Thymus-autonomous T cell development in the absence of progenitor import. J Exp Med 2012; 209(8):1409-17.

61. Zavidij O, Ball CR, Herbst F, Oppel F, Fessler S, Schmidt M, von Kalle C, Glimm H. Stable Long-Term Blood Formation by Stem Cells in Murine Steady-State Hematopoiesis. Stem Cells 2012; 30(9):1961-70.

62. Herpel E, Koleganova N, Schreiber B, Walter B, Kalle CV, Schirmacher P. Structural requirements of research tissue banks derived from standardized project surveillance. Virchows Arch 2012; 461(1):79-86.

63. Corrigan-Curay J, Cohen-Haguenauer O, O'Reilly M, Ross SR, Fan H, Rosenberg N, Somia N, King N, Friedmann T, Dunbar C, Aiuti A, Naldini L, Baum C, von Kalle C, Kiem HP, Montini E, Bushman F, Sorrentino BP, Carrondo M, Malech H, Gahrton G, Shapiro R, Wolff L, Rosenthal E, Jambou R, Zaia J, Kohn DB. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther 2012; 20(6):1084-94.

64. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366(21):2038-40.

65. Arens A, Appelt JU, Bartholomae CC, Gabriel R, Paruzynski A, Gustafson D, Cartier N, Aubourg P, Deichmann A, Glimm H, von Kalle C, Schmidt M. Bioinformatic Clonality Analysis of Next-Generation Sequencing-Derived Viral Vector Integration Sites. Hum Gene Ther Methods 2012; 23(2):111-8.

66. Herbst F, Ball CR, Tuorto F, Nowrouzi A, Wang W, Zavidij O, Dieter SM, Fessler S, van der Hoeven F, Kloz U, Lyko F, Schmidt M, von Kalle C, Glimm H. Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo. Mol Ther 2012; 20(5):1014-21.

67. Pincha M, Sai Sundarasetty B, Salguero G, Gutzmer R, Garritsen H, Macke L, Schneider A, Lenz D, Figueiredo C, Blasczyk R, Ruggiero E, Schmidt M, von Kalle C, Puff C, Modlich U, von der Leyen H, Wicke DC, Ganser A, Stripecke R. Identity, potency, in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapy. Hum Gene Ther Methods 2012; 23(1):38-55.

68. Nowrouzi A, Penaud-Budloo M, Kaeppel C, Appelt U, Le Guiner C, Moullier P, Kalle Cv, Snyder RO, Schmidt M. Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther 2012; 20(6):1177-86.

69. Schossig A, Wolf NI, Fischer C, Fischer M, Stocker G, Pabinger S, Dander A, Steiner B, Tönz O, Kotzot D, Haberlandt E, Amberger A, Burwinkel B, Wimmer K, Fauth C, Grond-Ginsbach C, Koch MJ, Deichmann A, von Kalle C, Bartram CR, Kohlschütter A, Trajanoski Z, Zschocke J. Mutations in ROGDI Cause Kohlschütter-Tönz Syndrome. Am J Hum Genet 2012; 90(4):701-7.

70. Grüllich C, von Kalle C. Recent developments and future perspectives of personalized oncology. Onkologie 2012; 35 Suppl 1:4-7.

71. Zaoui K, Bossow S, Grossardt C, Leber MF, Springfeld C, Plinkert PK, von Kalle C, Ungerechts G. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. Cancer Gene Ther 2012; 19(3):181-91.

Prof. Dr. Christof von Kalle